Yoshimitsu Kuroyanagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yoshimitsu Kuroyanagi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Kentaro Kubo
R&D Center for Artificial Skin, School of Allied Health Sciences, Kitasato University, Sagamihara, Kanagawa, Japan
5 shared publicationsRyusuke Suzuki
R&D Center for Artificial Skin , School of Allied Health Sciences, Kitasato University , Sagamihara , Japan
3 shared publicationsHayato Niiyama
R&D Center for Artificial Skin, School of Allied Health Sciences, Kitasato University, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan
2 shared publicationsAkane Yu
R&D Center for Artificial Skin, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan
1 shared publicationAkiko Hashimoto
Research and Development Center for Artificial Skin, School of Allied Health Sciences, Kitasato University, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan
1 shared publicationAkiko Yamamoto
R&D Center for Artificial Skin , School of Allied Health Sciences, Kitasato University , Sagamihara , Japan
1 shared publication
Latest Publications
- 1 December 2013
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 17 (1) , 81-87
Development of novel wound dressing composed of hyaluronic acid and collagen sponge containing epidermal growth factor and vitamin C derivative
This study was designed to investigate the potential of a wound dressing composed of hyaluronic acid (HA) and collagen (Col) spongy sheet containing epidermal growth factor (EGF) and vitamin C derivative (VC). High-molecular-weight HA aqueous solution, hydrolyzed low-molecular-weight HA aqueous solution and heat-denatured Col aqueous solution were mixed, followed by freeze-drying to obtain a spongy sheet. Cross-linkage between Col molecules was induced by UV irradiation of the spongy sheet (C-wound dressing). In a similar manner, three types of spongy sheet containing EGF (EGF-wound dressing), containing VC (VC-wound dressing) or containing EGF and VC (EGF·VC-wound dressing) were prepared by freeze-drying the mixed solution containing the specified components. Cytokine production by fibroblasts was assessed in a wound surface model using a fibroblast-incorporating Col gel sheet (cultured dermal substitute; CDS). CDS was elevated to the air–medium interface, onto which each wound dressing was placed and cultured for 7 days. Fibroblasts in CDS covered with EGF-wound dressing released 3.6 times more VEGF and 3.0 times more HGF, as compared with the C-wound dressing. Fibroblasts in CDS covered with EGF·VC-wound dressing released 4.2 times more VEGF and 6.0 times more HGF, as compared with the C-wound dressing. The efficacy of these wound dressings was evaluated in animal tests using diabetic mice. Each wound dressing was applied to a full-thickness skin defect on the dorsal area measuring 1.5 × 2.0 cm. After 1 week of application, wound conditions were evaluated histologically. The EGF·VC-wound dressing more effectively promoted granulation tissue formation associated with angiogenesis, as compared with other wound dressings.
- 1 December 2013
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 17 (1) , 81-87
Development of novel wound dressing composed of hyaluronic acid and collagen sponge containing epidermal growth factor and vitamin C derivative
This study was designed to investigate the potential of a wound dressing composed of hyaluronic acid (HA) and collagen (Col) spongy sheet containing epidermal growth factor (EGF) and vitamin C derivative (VC). High-molecular-weight HA aqueous solution, hydrolyzed low-molecular-weight HA aqueous solution and heat-denatured Col aqueous solution were mixed, followed by freeze-drying to obtain a spongy sheet. Cross-linkage between Col molecules was induced by UV irradiation of the spongy sheet (C-wound dressing). In a similar manner, three types of spongy sheet containing EGF (EGF-wound dressing), containing VC (VC-wound dressing) or containing EGF and VC (EGF·VC-wound dressing) were prepared by freeze-drying the mixed solution containing the specified components. Cytokine production by fibroblasts was assessed in a wound surface model using a fibroblast-incorporating Col gel sheet (cultured dermal substitute; CDS). CDS was elevated to the air–medium interface, onto which each wound dressing was placed and cultured for 7 days. Fibroblasts in CDS covered with EGF-wound dressing released 3.6 times more VEGF and 3.0 times more HGF, as compared with the C-wound dressing. Fibroblasts in CDS covered with EGF·VC-wound dressing released 4.2 times more VEGF and 6.0 times more HGF, as compared with the C-wound dressing. The efficacy of these wound dressings was evaluated in animal tests using diabetic mice. Each wound dressing was applied to a full-thickness skin defect on the dorsal area measuring 1.5 × 2.0 cm. After 1 week of application, wound conditions were evaluated histologically. The EGF·VC-wound dressing more effectively promoted granulation tissue formation associated with angiogenesis, as compared with other wound dressings.
- 8 September 2013
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 16 (4) , 489-494
Potential of wound dressing composed of hyaluronic acid containing epidermal growth factor to enhance cytokine production by fibroblasts
This study aimed to investigate the potential of a wound dressing composed of hyaluronic acid (HA) containing epidermal growth factor (EGF) to enhance cytokine production by fibroblasts. The present wound dressing has a two-layered spongy structure: an upper layer composed of crosslinked high-molecular-weight HA, and a lower layer composed of low-molecular-weight HA containing arginine (Arg) and vitamin C derivative (VC) with or without EGF. Human fibroblast-embedded collagen gel sheet (cultured dermal substitute: CDS) was elevated to the interface between the air and culture medium to create a wound surface model onto which each wound dressing was placed, which was followed by culture for 7 days. The EGF dressing (with EGF, Arg, VC) significantly enhanced the production of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) by CDS as compared to the EGF-free dressing (with Arg, VC). To evaluate if this enhanced production of VEGF and HGF achieved with the EGF dressing is sustained, a second experiment was conducted using a wound surface model. Each wound dressing was placed on the CDS in the wound surface model. Culture was then performed for 3 days (first period), after which each dressing was placed on another CDS for a further 3-day culture period (second period). The EGF dressing enhanced the production of VEGF and HGF by CDS during the first and second periods as compared to the corresponding production when using the EGF-free dressing. These results suggest that EGF can be maintained in the hydrated layer of a wound dressing composed of crosslinked high-molecular-weight HA.
- 8 September 2013
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 16 (4) , 489-494
Potential of wound dressing composed of hyaluronic acid containing epidermal growth factor to enhance cytokine production by fibroblasts
This study aimed to investigate the potential of a wound dressing composed of hyaluronic acid (HA) containing epidermal growth factor (EGF) to enhance cytokine production by fibroblasts. The present wound dressing has a two-layered spongy structure: an upper layer composed of crosslinked high-molecular-weight HA, and a lower layer composed of low-molecular-weight HA containing arginine (Arg) and vitamin C derivative (VC) with or without EGF. Human fibroblast-embedded collagen gel sheet (cultured dermal substitute: CDS) was elevated to the interface between the air and culture medium to create a wound surface model onto which each wound dressing was placed, which was followed by culture for 7 days. The EGF dressing (with EGF, Arg, VC) significantly enhanced the production of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) by CDS as compared to the EGF-free dressing (with Arg, VC). To evaluate if this enhanced production of VEGF and HGF achieved with the EGF dressing is sustained, a second experiment was conducted using a wound surface model. Each wound dressing was placed on the CDS in the wound surface model. Culture was then performed for 3 days (first period), after which each dressing was placed on another CDS for a further 3-day culture period (second period). The EGF dressing enhanced the production of VEGF and HGF by CDS during the first and second periods as compared to the corresponding production when using the EGF-free dressing. These results suggest that EGF can be maintained in the hydrated layer of a wound dressing composed of crosslinked high-molecular-weight HA.
- 25 September 2012
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 24 (8) , 1015-1026
Wound dressing composed of hyaluronic acid and collagen containing EGF or bFGF: comparative culture study
We developed a novel wound dressing composed of a hyaluronic acid (HA) and collagen (Col) spongy sheet containing epidermal growth factor (EGF) or basic fibrolast growth factor (bFGF) by freeze-drying method (EGF-wound dressing or bFGF-wound dressing, respectively). A wound dressing without any growth factor was prepared as a control in a similar manner as above (C-wound dressing). Intermolecular cross-linkage between Col molecules was induced by UV irradiation. The release behavior of free HA from the wound dressing was investigated using a C-wound dressing. The weight of C-wound dressing after 1 day, 3, 5, and 7 days of incubation on top of a Col gel sheet at the air–water interface (wound surface model) was 55, 36, 30, and 19% of the original weight, respectively. Most free HA and a part of Col was released from the cross-linked Col network in the wound dressing during incubation, as the original Col content in the wound dressing was 33%. Next, fibroblast proliferation was assessed in conventional culture medium preconditioned by immersion of a piece of C-, EGF-, or bFGF-wound dressing, i.e. C-conditioned medium, EGF-conditioned medium, or bFGF-conditioned medium. Cell proliferation in C-conditioned medium increased to approximately the same level as that in conventional medium. Cell proliferation in EGF- and bFGF-conditioned medium was 1.9 times and 2.6 times greater than that in conventional medium after 7 days of cultivation, respectively. Finally, cytokine production of fibroblasts was assessed in a wound surface model using a fibroblast-incorporating Col gel sheet (cultured dermal substitute [CDS]). CDS was elevated to the air–medium interface, on which each wound dressing was placed and cultured for 7 days. Fibroblasts in CDS covered with EGF-wound dressing released 3.6 times more vascular endothelial growth factor (VEGF) and 4.6 times more hepatocyte growth factor (HGF) when compared with the C-wound dressing. Fibroblasts in CDS covered with bFGF-wound dressing released 10.2 times more VEGF and 6.3 times more HGF when compared with the C-wound dressing. This finding indicates that bFGF-wound dressing can facilitate more effectively the VEGF and FGF production compared with EGF-wound dressing.
- 25 September 2012
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 24 (8) , 1015-1026
Wound dressing composed of hyaluronic acid and collagen containing EGF or bFGF: comparative culture study
We developed a novel wound dressing composed of a hyaluronic acid (HA) and collagen (Col) spongy sheet containing epidermal growth factor (EGF) or basic fibrolast growth factor (bFGF) by freeze-drying method (EGF-wound dressing or bFGF-wound dressing, respectively). A wound dressing without any growth factor was prepared as a control in a similar manner as above (C-wound dressing). Intermolecular cross-linkage between Col molecules was induced by UV irradiation. The release behavior of free HA from the wound dressing was investigated using a C-wound dressing. The weight of C-wound dressing after 1 day, 3, 5, and 7 days of incubation on top of a Col gel sheet at the air–water interface (wound surface model) was 55, 36, 30, and 19% of the original weight, respectively. Most free HA and a part of Col was released from the cross-linked Col network in the wound dressing during incubation, as the original Col content in the wound dressing was 33%. Next, fibroblast proliferation was assessed in conventional culture medium preconditioned by immersion of a piece of C-, EGF-, or bFGF-wound dressing, i.e. C-conditioned medium, EGF-conditioned medium, or bFGF-conditioned medium. Cell proliferation in C-conditioned medium increased to approximately the same level as that in conventional medium. Cell proliferation in EGF- and bFGF-conditioned medium was 1.9 times and 2.6 times greater than that in conventional medium after 7 days of cultivation, respectively. Finally, cytokine production of fibroblasts was assessed in a wound surface model using a fibroblast-incorporating Col gel sheet (cultured dermal substitute [CDS]). CDS was elevated to the air–medium interface, on which each wound dressing was placed and cultured for 7 days. Fibroblasts in CDS covered with EGF-wound dressing released 3.6 times more vascular endothelial growth factor (VEGF) and 4.6 times more hepatocyte growth factor (HGF) when compared with the C-wound dressing. Fibroblasts in CDS covered with bFGF-wound dressing released 10.2 times more VEGF and 6.3 times more HGF when compared with the C-wound dressing. This finding indicates that bFGF-wound dressing can facilitate more effectively the VEGF and FGF production compared with EGF-wound dressing.
- 13 August 2012
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 24 (3) , 287-300
Safety and utility of a PMMA-based tissue adhesive for closure of surgical incision wounds
This study aimed to investigate the safety and utility of the polymethylmethacrylate (PMMA)-based tissue adhesive (PMMA-ta) for wound closure. This product is composed of 4-methacryloyloxyethyl trimellitate anhydride and methylmethacrylate as monomers, tri-n-butylborane as initiator, and PMMA powder as filler. These components are mixed at the time of use. This resulting paste hardens within several minutes. The safety of PMMA-ta was evaluated in an internal wound model using a cultured dermal substitute (CDS), i.e. a fibroblast-embedded collagen gel sheet. PMMA-ta was applied to one CDS, covered with a second CDS, and then cultured for 1 week (group II). A commercially available 2-octyl cyanoacrylate-based tissue adhesive (OCA) was used for comparative purposes (group I). No tissue adhesive was applied to the CDSs in the control group. Fibroblast viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell viability in the group I was 36%, and cell viability in the group II was 84%, of that in the control group. These results indicate that PMMA-ta has lower cytotoxicity than OCA. Next, the usefulness of PMMA-ta as a tissue adhesive was evaluated in three different wound models using Sprague–Dawley rats: (1) a thin skin incision wound, (2) a thick skin incision wound, and (3) a full-thickness incision wound through the abdominal wall. The third experiment is the surgical incision model with the most severe condition. The comparative study using OCA was conducted only in the third experiment. Each wound healing process was evaluated macroscopically and histologically after 1 week, 2 weeks, and 3 months. An excellent macroscopic wound appearance was observed with both PMMA-ta and OCA, with only a slightly visible fine-line scar. Histologically, a typical primary healing was observed for both adhesives. Considering its safety and utility, PMMA-ta is therefore promising for use as a tissue adhesive in wound closure.
- 13 August 2012
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 24 (3) , 287-300
Safety and utility of a PMMA-based tissue adhesive for closure of surgical incision wounds
This study aimed to investigate the safety and utility of the polymethylmethacrylate (PMMA)-based tissue adhesive (PMMA-ta) for wound closure. This product is composed of 4-methacryloyloxyethyl trimellitate anhydride and methylmethacrylate as monomers, tri-n-butylborane as initiator, and PMMA powder as filler. These components are mixed at the time of use. This resulting paste hardens within several minutes. The safety of PMMA-ta was evaluated in an internal wound model using a cultured dermal substitute (CDS), i.e. a fibroblast-embedded collagen gel sheet. PMMA-ta was applied to one CDS, covered with a second CDS, and then cultured for 1 week (group II). A commercially available 2-octyl cyanoacrylate-based tissue adhesive (OCA) was used for comparative purposes (group I). No tissue adhesive was applied to the CDSs in the control group. Fibroblast viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell viability in the group I was 36%, and cell viability in the group II was 84%, of that in the control group. These results indicate that PMMA-ta has lower cytotoxicity than OCA. Next, the usefulness of PMMA-ta as a tissue adhesive was evaluated in three different wound models using Sprague–Dawley rats: (1) a thin skin incision wound, (2) a thick skin incision wound, and (3) a full-thickness incision wound through the abdominal wall. The third experiment is the surgical incision model with the most severe condition. The comparative study using OCA was conducted only in the third experiment. Each wound healing process was evaluated macroscopically and histologically after 1 week, 2 weeks, and 3 months. An excellent macroscopic wound appearance was observed with both PMMA-ta and OCA, with only a slightly visible fine-line scar. Histologically, a typical primary healing was observed for both adhesives. Considering its safety and utility, PMMA-ta is therefore promising for use as a tissue adhesive in wound closure.
- 6 August 2012
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 24 (6) , 726-740
Development of an artificial dermis composed of hyaluronic acid and collagen
This study aimed to investigate the efficacy of an artificial dermis composed of hyaluronic acid (HA) and collagen (Col) with or without epidermal growth factor (EGF), both in in vitro and in vivo. The cross-linked high molecular weight HA spongy sheet was prepared by freeze-drying. The spongy sheet was immersed in a mixed solution of high molecular weight HA, low molecular weight HA, and heat-denatured Col, and then lyophilized to obtain a two-layered spongy sheet. Cross-linking among Col molecules was induced by ultraviolet irradiation to prepare the artificial dermis (Type I). In a similar manner, a two-layered artificial dermis containing EGF (Type II) was prepared using a similar mixed solution containing EGF. The in vitro experiments demonstrated that EGF released from the Type II artificial dermis stimulates fibroblasts to produce increased amounts of vascular endothelial growth factor and hepatocyte growth factor. The therapeutic efficacy of artificial dermis was evaluated in animal tests using Sprague Dawley (SD) rats. The dorsal skin of the SD rat was shaved and then exposed to boiling water for 3 s to induce a deep dermal burn. The necrotic tissue was then excised 3 days later. Each artificial dermis was applied to the skin defect for 7 days and assessed for its ability to generate a wound bed. The in vivo experiments demonstrated that the Type II artificial dermis promotes angiogenesis to a greater extent at an early stage (within 3 days), and also suppresses the inflammatory reaction more successfully compared with the Type I artificial dermis. In further animal tests, an autologous skin graft was performed by excising a piece of skin from the abdominal region and then grafting it onto the wound bed prepared using each artificial dermis for 7 days. Although the Type II artificial dermis had the highest potential to promote angiogenesis, in this animal study, each artificial dermis induced excellent wound bed formation acceptable for autologous skin grafting.
- 6 August 2012
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 24 (6) , 726-740
Development of an artificial dermis composed of hyaluronic acid and collagen
This study aimed to investigate the efficacy of an artificial dermis composed of hyaluronic acid (HA) and collagen (Col) with or without epidermal growth factor (EGF), both in in vitro and in vivo. The cross-linked high molecular weight HA spongy sheet was prepared by freeze-drying. The spongy sheet was immersed in a mixed solution of high molecular weight HA, low molecular weight HA, and heat-denatured Col, and then lyophilized to obtain a two-layered spongy sheet. Cross-linking among Col molecules was induced by ultraviolet irradiation to prepare the artificial dermis (Type I). In a similar manner, a two-layered artificial dermis containing EGF (Type II) was prepared using a similar mixed solution containing EGF. The in vitro experiments demonstrated that EGF released from the Type II artificial dermis stimulates fibroblasts to produce increased amounts of vascular endothelial growth factor and hepatocyte growth factor. The therapeutic efficacy of artificial dermis was evaluated in animal tests using Sprague Dawley (SD) rats. The dorsal skin of the SD rat was shaved and then exposed to boiling water for 3 s to induce a deep dermal burn. The necrotic tissue was then excised 3 days later. Each artificial dermis was applied to the skin defect for 7 days and assessed for its ability to generate a wound bed. The in vivo experiments demonstrated that the Type II artificial dermis promotes angiogenesis to a greater extent at an early stage (within 3 days), and also suppresses the inflammatory reaction more successfully compared with the Type I artificial dermis. In further animal tests, an autologous skin graft was performed by excising a piece of skin from the abdominal region and then grafting it onto the wound bed prepared using each artificial dermis for 7 days. Although the Type II artificial dermis had the highest potential to promote angiogenesis, in this animal study, each artificial dermis induced excellent wound bed formation acceptable for autologous skin grafting.
- 8 May 2012
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 24 (2) , 224-238
Potential of a Cryopreserved Cultured Dermal Substitute Composed of Hyaluronic Acid and Collagen to Release Angiogenic Cytokine
An allogeneic cultured dermal substitute (CDS) was prepared by culturing fibroblasts on a spongy matrix of hyaluronic acid (HA) and collagen (Col), which was then cryopreserved. This cryopreserved ...
- 8 May 2012
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 24 (2) , 224-238
Potential of a Cryopreserved Cultured Dermal Substitute Composed of Hyaluronic Acid and Collagen to Release Angiogenic Cytokine
An allogeneic cultured dermal substitute (CDS) was prepared by culturing fibroblasts on a spongy matrix of hyaluronic acid (HA) and collagen (Col), which was then cryopreserved. This cryopreserved ...
- 17 December 2008
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 11 (4) , 225-231
Standardization for mass production of allogeneic cultured dermal substitute by measuring the amount of VEGF, bFGF, HGF, TGF-β, and IL-8
Fibroblasts were isolated from a piece of donated skin measuring about 1 × 1 cm and were proliferated over nine successive cultivations. Fibroblasts obtained from the fourth cultivation were cryopreserved in 10 cryotubes as master cells. Fibroblasts obtained from the fifth to ninth cultivations were cryopreserved in 49 cryotubes in total as working cells. At the end of each procedure in the fourth to eighth cultivations, about three-quarters of the proliferated fibroblasts were cryopreserved, and the remaining one-quarter were proliferated in the next cultivation. All fibroblasts obtained from the ninth (final) procedure were cryopreserved as the last working cells. Two cryotubes of the last cryopreserved working cells (ninth cultivation) were thawed and proliferated. Cultured dermal substitute (CDS) was prepared by performing ten successive cultivations. After each cultivation, about three-quarters of the resulting fibroblasts were used to prepare CDS, and the remaining one-quarter were proliferated in the next cultivation for 1 week. Finally, all fibroblasts produced by the tenth (final) procedure were used to prepare CDS. In each of the first to ninth cultivations for CDS preparation, the density of fibroblasts remained relatively constant, and the levels of cytokines, i.e., vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor, transforming growth factor-beta 1, and interleukin-8 released from CDS remained relatively constant. In total, 47 sheets of CDS measuring 10 × 10 cm were prepared. The present findings indicate that about 1000 sheets of CDS measuring 10 × 10 cm can be prepared using all the working cells prepared from a piece of donated skin measuring 1 × 1 cm.
- 17 December 2008
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 11 (4) , 225-231
Standardization for mass production of allogeneic cultured dermal substitute by measuring the amount of VEGF, bFGF, HGF, TGF-β, and IL-8
Fibroblasts were isolated from a piece of donated skin measuring about 1 × 1 cm and were proliferated over nine successive cultivations. Fibroblasts obtained from the fourth cultivation were cryopreserved in 10 cryotubes as master cells. Fibroblasts obtained from the fifth to ninth cultivations were cryopreserved in 49 cryotubes in total as working cells. At the end of each procedure in the fourth to eighth cultivations, about three-quarters of the proliferated fibroblasts were cryopreserved, and the remaining one-quarter were proliferated in the next cultivation. All fibroblasts obtained from the ninth (final) procedure were cryopreserved as the last working cells. Two cryotubes of the last cryopreserved working cells (ninth cultivation) were thawed and proliferated. Cultured dermal substitute (CDS) was prepared by performing ten successive cultivations. After each cultivation, about three-quarters of the resulting fibroblasts were used to prepare CDS, and the remaining one-quarter were proliferated in the next cultivation for 1 week. Finally, all fibroblasts produced by the tenth (final) procedure were used to prepare CDS. In each of the first to ninth cultivations for CDS preparation, the density of fibroblasts remained relatively constant, and the levels of cytokines, i.e., vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor, transforming growth factor-beta 1, and interleukin-8 released from CDS remained relatively constant. In total, 47 sheets of CDS measuring 10 × 10 cm were prepared. The present findings indicate that about 1000 sheets of CDS measuring 10 × 10 cm can be prepared using all the working cells prepared from a piece of donated skin measuring 1 × 1 cm.
- 1 May 2004
- Published by Wiley in Artificial Organs
- Vol. 28 (5) , 444-450
Treatment of Full‐thickness Skin Defect with Concomitant Grafting of 6‐fold Extended Mesh Auto‐skin and Allogeneic Cultured Dermal Substitute
- 1 May 2004
- Published by Wiley in Artificial Organs
- Vol. 28 (5) , 444-450
Treatment of Full‐thickness Skin Defect with Concomitant Grafting of 6‐fold Extended Mesh Auto‐skin and Allogeneic Cultured Dermal Substitute
- 13 February 2004
- Published by Wiley in Artificial Organs
- Vol. 28 (2) , 182-188
Development of a Cultured Dermal Substitute Composed of a Spongy Matrix of Hyaluronic Acid and Atelo‐collagen Combined with Fibroblasts: Cryopreservation
An allogeneic cultured dermal substitute (CDS) was prepared by cultivating fibroblasts on a two‐layered spongy matrix of hyaluronic acid (HA) and atelo‐collagen (Col). The ability of fibroblasts to secrete cytokines is dependent on the conditions of freezing and thawing. The first experiment was designed to investigate the effects of supplements in a cryoprotective medium, that is, dimethylsulfoxide (DMSO), glycerol, and fetal bovine serum (FBS). In each experiment we measured the cell viability after thawing and the cell growth in CDS recultured after thawing. In addition, the amount of vascular endothelial growth factor (VEGF) released from the CDS recultured for one week after thawing was measured. The highest values of cell viability, cell growth, and the amount of VEGF released were obtained when CDS was frozen in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% DMSO and 40% FBS, and then thawed quickly in a water bath at 37°C. However, due to the high cost of FBS, in clinical applications CDS is usually frozen in DMEM supplemented with 10% DMSO and 20% FBS. In practice, however, physicians often cannot use CDS immediately after thawing, depending on clinical conditions. Therefore, in the second experiment we investigated cell viability at different time points after thawing. In addition, we investigated cell growth and the amount of VEGF released from fibroblasts in CDS at different time points after thawing under different conditions, and after further reculturing for one week. We recommend that CDS be rinsed with lactated Ringer's solution immediately after thawing, and that it be used within 4 h after thawing.
- 13 February 2004
- Published by Wiley in Artificial Organs
- Vol. 28 (2) , 182-188
Development of a Cultured Dermal Substitute Composed of a Spongy Matrix of Hyaluronic Acid and Atelo‐collagen Combined with Fibroblasts: Cryopreservation
An allogeneic cultured dermal substitute (CDS) was prepared by cultivating fibroblasts on a two‐layered spongy matrix of hyaluronic acid (HA) and atelo‐collagen (Col). The ability of fibroblasts to secrete cytokines is dependent on the conditions of freezing and thawing. The first experiment was designed to investigate the effects of supplements in a cryoprotective medium, that is, dimethylsulfoxide (DMSO), glycerol, and fetal bovine serum (FBS). In each experiment we measured the cell viability after thawing and the cell growth in CDS recultured after thawing. In addition, the amount of vascular endothelial growth factor (VEGF) released from the CDS recultured for one week after thawing was measured. The highest values of cell viability, cell growth, and the amount of VEGF released were obtained when CDS was frozen in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% DMSO and 40% FBS, and then thawed quickly in a water bath at 37°C. However, due to the high cost of FBS, in clinical applications CDS is usually frozen in DMEM supplemented with 10% DMSO and 20% FBS. In practice, however, physicians often cannot use CDS immediately after thawing, depending on clinical conditions. Therefore, in the second experiment we investigated cell viability at different time points after thawing. In addition, we investigated cell growth and the amount of VEGF released from fibroblasts in CDS at different time points after thawing under different conditions, and after further reculturing for one week. We recommend that CDS be rinsed with lactated Ringer's solution immediately after thawing, and that it be used within 4 h after thawing.
- 9 January 2004
- Published by Wiley in Artificial Organs
- Vol. 28 (1) , 13-21
Establishment of Banking System for Allogeneic Cultured Dermal Substitute
Abstract: Allogeneic cultured dermal substitute (CDS) was prepared by culturing fibroblasts on a two‐layered spongy matrix of hyaluronic acid (HA) and atelo‐collagen (Col). Allogeneic CDS can be cryopreserved and transported to other hospitals in a frozen state. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), platelet derived growth factor (PDGF)‐AA, transforming growth factor (TGF)‐β1, keratinocytes growth factor (KGF), interleukin (IL)‐6 and IL‐8 were contained in the culture medium which was used in preparing CDS over a cultivation period of one week (fresh CDS culture medium sample). After thawing a cryopreserved CDS, the CDS was recultured in a culture medium for one week. VEGF, bFGF, HGF, TGF‐β1 and IL‐8 were contained in the culture medium which was used in reculturing CDS for one week (cryopreserved CDS culture medium sample), although some cytokines were detected at a lower level than those before freezing. This finding suggests that the cryopreserved CDS retains its ability to release these cytokines.Clinical research on allogeneic CDS, which was newly developed at the R & D Center for Artificial Skin of Kitasato University, has been carried out in medical centers across Japan with the support of the Millennium Project of the Ministry of Health, Labor and Welfare. It was demonstrated that the allogeneic CDS functions as an excellent cell therapy for intractable skin ulcers as well as burn injuries. The spongy matrix itself, as well as the cytokines released from the allogeneic CDS, seemed to be beneficial for the treatment of intractable skin defect.
- 9 January 2004
- Published by Wiley in Artificial Organs
- Vol. 28 (1) , 13-21
Establishment of Banking System for Allogeneic Cultured Dermal Substitute
Abstract: Allogeneic cultured dermal substitute (CDS) was prepared by culturing fibroblasts on a two‐layered spongy matrix of hyaluronic acid (HA) and atelo‐collagen (Col). Allogeneic CDS can be cryopreserved and transported to other hospitals in a frozen state. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), platelet derived growth factor (PDGF)‐AA, transforming growth factor (TGF)‐β1, keratinocytes growth factor (KGF), interleukin (IL)‐6 and IL‐8 were contained in the culture medium which was used in preparing CDS over a cultivation period of one week (fresh CDS culture medium sample). After thawing a cryopreserved CDS, the CDS was recultured in a culture medium for one week. VEGF, bFGF, HGF, TGF‐β1 and IL‐8 were contained in the culture medium which was used in reculturing CDS for one week (cryopreserved CDS culture medium sample), although some cytokines were detected at a lower level than those before freezing. This finding suggests that the cryopreserved CDS retains its ability to release these cytokines.Clinical research on allogeneic CDS, which was newly developed at the R & D Center for Artificial Skin of Kitasato University, has been carried out in medical centers across Japan with the support of the Millennium Project of the Ministry of Health, Labor and Welfare. It was demonstrated that the allogeneic CDS functions as an excellent cell therapy for intractable skin ulcers as well as burn injuries. The spongy matrix itself, as well as the cytokines released from the allogeneic CDS, seemed to be beneficial for the treatment of intractable skin defect.